ARCHIVES

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

This article is from The Cancer Letter archive.

Vol. 35 No. 12 | December 28, 2012

Download PDF Visit The Full Archive

Related Articles

National Cancer Survey Data Available Soon: NCI Will Invite Investigators to Prepare Analysis

August 23, 1974

Phase III Cyramza Trial Meets OS Primary Endpoint

September 26, 2014

Bill Requires NIH-Funded Researchers To Send Manuscripts To PubMed Central.

November 2, 2007

National Action Plan Issues Complete List Of Breast Cancer Funding Mechanisms

May 26, 1995

Reinventing NCI: Natural Products Screen Closes; NCI Targets Drug Resistance

December 13, 1996

Includes 8-page Business & Regulatory Report.

April 11, 2003